Quince Therapeutics Inc (QNCX) News
Follow Quince Therapeutics Inc (QNCX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 17 public stories across 13 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Quince Therapeutics Price Target Announced at $70.00/Share by Rodman & Renshaw
Ratings actions from Benzinga: GMT) Quince Therapeutics Initiated at Buy by Rodman & RenshawRatings actions from Benzinga
NEWS | Sep 24, 2026, 11:51 AM UTC
M
Citizens upgrades Quince Therapeutics to Market Outperform, $77 target
Citizens upgraded Quince Therapeutics to Market Outperform and set a $77.00 price target, implying 148.4% upside from the Sep 21 close of $31.00.
EQUITY | Sep 22, 2026, 12:50 PM UTC
L
QNCX - Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
QNCX - Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
NEWS | Sep 17, 2026, 12:00 PM UTC
L
Quince Therapeutics' Charles Ryan to Depart; Receives $1.014M Severance
Quince Therapeutics' President Charles Ryan departed effective September 8, 2026, under a Separation Agreement providing a $1,014,489.04 lump-sum severance payment.Original SEC Filing: Quince Therapeutics, Inc. [ QNCX ]
REGULATION | Sep 14, 2026, 08:46 PM UTC
L
QNCX: LAM-001 shows promise as an inhaled mTOR inhibitor for multiple pulmonary diseases, with pivotal data ahead
LAM-001, an inhaled mTOR inhibitor, is advancing through clinical trials for BOS, PH-ILD, and SAPH, with strong KOL support and promising early data. Key readouts are expected in Q1 2027 for BOS and Q1 2028 for PH-ILD, t
EQUITY | Sep 09, 2026, 08:12 PM UTC
L
QNCX: LAM-001 shows promise as a once-daily inhaled therapy for multiple high-need pulmonary diseases
LAM-001, a once-daily inhaled rapamycin, is advancing through clinical trials for BOS, PH-ILD, and SAPH, with key data readouts expected in 2027 and 2028. Early results show strong pulmonary delivery, low systemic exposu
EQUITY | Sep 09, 2026, 07:43 PM UTC
M
Quince Therapeutics gets Nasdaq notice over equity shortfall
Nasdaq notified Quince Therapeutics it failed Listing Rule 5450(b)(1)(A) after stockholders’ equity of ($35.3M), below the $10M minimum. Shares continue on Nasdaq Global Select Market under QNCX; company has until Octobe
EQUITY | Sep 04, 2026, 12:34 PM UTC
L
Quince Therapeutics to participate in September 2026 investor conferences
Quince Therapeutics said senior management will participate in September 2026 investor conferences, according to the company’s announcement.
EQUITY | Sep 03, 2026, 12:07 PM UTC
L
QNCX - Quince Therapeutics to Participate in September 2026 Investor Conferences
QNCX - Quince Therapeutics to Participate in September 2026 Investor Conferences
EQUITY | Sep 03, 2026, 12:01 PM UTC
L
Quince Therapeutics president Charles Ryan to depart Sept 8, 2026
Charles Ryan will depart as president on Sept 8, 2026.
EQUITY | Aug 27, 2026, 08:35 PM UTC
L
Craig-Hallum initiates QNCX at Buy, sets $68.00 target
Craig-Hallum initiates coverage of QNCX with a Buy rating and a $68.00 price target.
EQUITY | Aug 20, 2026, 11:56 AM UTC
L
Quince Therapeutics reports Q2 2026 financial results update
Quince Therapeutics (QNCX) reports Second Quarter 2026 financial results and provides a corporate update, according to TradeXchange Newsdesk.
EARNINGS | Aug 14, 2026, 12:00 PM UTC
L
SEC Filings: Multiple Companies
Multiple companies file with SEC
EQUITY | Aug 03, 2026, 09:28 AM UTC
L
QNCX Initiated Outperform and $82 PT @ OPCO
QNCX Initiated Outperform and $82 PT @ OPCO
EQUITY | Jul 29, 2026, 12:52 PM UTC
L
QNCX Initiated Outperform W/$82.00 PT at Oppenheimer
QNCX Initiated Outperform W/$82.00 PT at Oppenheimer
EQUITY | Jul 29, 2026, 11:59 AM UTC
H
Analysts Initiate Buys
Analysts initiate buy ratings
EQUITY | Jul 29, 2026, 11:15 AM UTC
M
Banks Initiate Coverage
Multiple banks initiate coverage on various stocks with OUTPERFORM, BUY, and EQUAL WEIGHT ratings
EQUITY | Jun 24, 2026, 10:54 AM UTC